Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

Mishra, Rasmi; Belder, Nevin; Ansari, Suhail; Kayhan, Merve; Bal, Hilal; Raza, Umar; Ersan, Pelin; Tokat, Unal; Eyupoglu, Erol; Saatci, Ozge; Jandaghi, Pouria; Wiemann, Stefan; ÜNER, AYŞEGÜL; ÇEKİÇ, ÇAĞLAR; Riazalhosseini, Yasser; ŞAHİN, ÖZGÜR

doi:10.1158/1078-0432.ccr-17-2776

Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

Mishra R. R., Belder N., Ansari S. A., Kayhan M., Bal H., Raza U., ...More

CLINICAL CANCER RESEARCH, vol.24, no.8, pp.1987-2001, 2018 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 24 Issue: 8
Publication Date: 2018
Doi Number: 10.1158/1078-0432.ccr-17-2776
Journal Name: CLINICAL CANCER RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1987-2001
Open Archive Collection: AVESIS Open Access Collection
Hacettepe University Affiliated: Yes

Abstract

Purpose: Tamoxifen remains an important hormonal therapy for ER-positive breast cancer; however, development of resistance is a major obstacle in clinics. Here, we aimed to identify novel mechanisms of tamoxifen resistance and provide actionable drug targets overcoming resistance.